文献速递慢性肾脏病肾血管病与高血压

1型糖尿病中白蛋白尿变化与心血管及肾脏结局:DCCT/EDIC研究

Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2016-10-24

在1441例1型糖尿病患者中,持续微量白蛋白尿、缓解的微量白蛋白尿和大量白蛋白尿均与心血管事件和eGFR降低风险升高相关,但已确立的微量白蛋白尿缓解至正常白蛋白尿未改善结局。

要点

  • 持续微量白蛋白尿、缓解的微量白蛋白尿和大量白蛋白尿均与心血管事件风险升高相关。
  • 大量白蛋白尿与eGFR降低风险显著升高相关(校正HR 54.35)。
  • 微量白蛋白尿缓解至正常白蛋白尿未降低心血管事件或eGFR降低风险。

核心结论

  • 在1型糖尿病中,微量白蛋白尿和大量白蛋白尿与心血管疾病和eGFR降低风险升高相关,但已确立的微量白蛋白尿缓解至正常白蛋白尿似乎未改善结局。

研究设计与样本

  • 研究纳入糖尿病控制与并发症试验/糖尿病干预与并发症流行病学研究(DCCT/EDIC)的1441例参与者,每年或每两年定量白蛋白排泄率(AER)长达30年。

主要发现

  • 至少发生一次心血管事件者184例,98例出现eGFR降低。
  • 与正常白蛋白尿相比,持续微量白蛋白尿、缓解的微量白蛋白尿和大量白蛋白尿的心血管事件校正HR分别为1.79(95%CI 1.13-2.85)、2.62(95%CI 1.68-4.07)和2.65(95%CI 1.68-4.19)。
  • 与正常白蛋白尿相比,持续微量白蛋白尿、缓解的微量白蛋白尿和大量白蛋白尿的eGFR降低校正HR分别为5.26(95%CI 2.43-11.41)、4.36(95%CI 1.80-10.57)和54.35(95%CI 30.79-95.94)。
  • 与持续微量白蛋白尿相比,缓解至正常白蛋白尿的心血管事件校正HR为1.33(95%CI 0.68-2.59),eGFR降低校正HR为1.75(95%CI 0.56-5.49)。
  • 与正常白蛋白尿相比,持续微量白蛋白尿、缓解的微量白蛋白尿和大量白蛋白尿与更大的颈动脉内膜中层厚度相关,大量白蛋白尿与更大程度的冠状动脉钙化相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In trials of people with type 2 diabetes, albuminuria reduction with renin-angiotensin system inhibitors is associated with lower risks of cardiovascular events and CKD progression. We tested whether progression or remission of microalbuminuria is associated with cardiovascular and renal risk in a well characterized cohort of type 1 diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 1441 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Albumin excretion rate (AER) was quantified annually or biennially for up to 30 years. For each participant, albuminuria status was defined over time as normoalbuminuria (AER continuously <30 mg/d), sustained microalbuminuria (AER, 30-299 mg/d on two consecutive visits), macroalbuminuria (AER≥300 mg/d), or remitted microalbuminuria (transition from sustained microalbuminuria to AER<30 mg/d on two consecutive visits). We tested associations of time-updated albuminuria status with adjudicated clinical cardiovascular events, the development of reduced GFR (<60 ml/min per 1.73 m2 on two consecutive visits), and subclinical cardiovascular disease. RESULTS: At least one cardiovascular event occurred in 184 participants, and 98 participants developed reduced eGFR. Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were each associated with higher risk of cardiovascular events (adjusted hazard ratios [HRs] and 95% confidence intervals [95% CIs]: 1.79 [1.13 to 2.85], 2.62 [1.68 to 4.07], and 2.65 [1.68 to 4.19], respectively) and reduced eGFR (adjusted HRs [95% CIs], 5.26 [2.43 to 11.41], 4.36 [1.80 to 10.57], and 54.35 [30.79 to 95.94], respectively). Compared with sustained microalbuminuria, remission to normoalbuminuria was not associated with reduced risk of cardiovascular events (adjusted HR, 1.33; 95% CI, 0.68 to 2.59) or reduced eGFR (adjusted HR, 1.75; 95% CI, 0.56 to 5.49). Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were associated with greater carotid intima-media thickness, and macroalbuminuria was associated with a greater degree of coronary artery calcification. CONCLUSIONS: In type 1 diabetes, microalbuminuria and macroalbuminuria are associated with higher risks of cardiovascular disease and reduced eGFR, but achieving a remission of established microalbuminuria to normoalbuminuria does not appear to improve outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. de Boer IH, Gao X, Cleary PA, et al. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol. 2016. PMID: 27797889. doi:10.2215/CJN.02870316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。